PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
19365399-5	2009	Variants in the norepinephrine transporter gene (SLC6A2) predicted response to nortriptyline, and variants in the glucocorticoid receptor gene (NR3C1) predicted response to both antidepressants.	Nortriptyline	79-92	solute carrier family 6 member 2	Homo sapiens	16-42
19641488-8	2009	Among men taking nortriptyline, suicidality was also associated with rs11195419 SNP in the alpha(2A)-adrenergic receptor gene (ADRA2A) (p=0.007).	Nortriptyline	17-30	adrenoceptor alpha 2A	Homo sapiens	127-133
19365399-5	2009	Variants in the norepinephrine transporter gene (SLC6A2) predicted response to nortriptyline, and variants in the glucocorticoid receptor gene (NR3C1) predicted response to both antidepressants.	Nortriptyline	79-92	solute carrier family 6 member 2	Homo sapiens	49-55
19567893-4	2009	METHOD: The 5-HTTLPR and 13 additional markers across the serotonin transporter gene were genotyped in 795 adults with moderate-to-severe depression treated with escitalopram or nortriptyline in the Genome Based Therapeutic Drugs for Depression (GENDEP) project.	Nortriptyline	178-191	solute carrier family 6 member 4	Homo sapiens	58-79
19449410-2	2009	We report on a set of identical twins with a de novo C749G mutation in the FGFR3 gene codon 250 after a pregnancy complicated by prenatal exposure to Nortriptyline.	Nortriptyline	150-163	fibroblast growth factor receptor 3	Homo sapiens	75-80
19259968-10	2009	On the contrary, the beta-AR antagonists propranolol or sotalol, the beta(1)/beta(2)-AR antagonists alprenolol or pindolol, or the specific beta(2)-AR antagonist ICI 118,551 blocked the action of nortriptyline.	Nortriptyline	196-209	adrenergic receptor, beta 2	Mus musculus	77-87
19259968-10	2009	On the contrary, the beta-AR antagonists propranolol or sotalol, the beta(1)/beta(2)-AR antagonists alprenolol or pindolol, or the specific beta(2)-AR antagonist ICI 118,551 blocked the action of nortriptyline.	Nortriptyline	196-209	adrenergic receptor, beta 2	Mus musculus	140-150
19259968-11	2009	The effect of nortriptyline was also totally absent in beta(2)-AR-deficient mice.	Nortriptyline	14-27	adrenergic receptor, beta 2	Mus musculus	55-65
19259968-12	2009	INTERPRETATION: Stimulation of beta(2)-AR is necessary for nortriptyline to exert its antiallodynic action against neuropathic pain.	Nortriptyline	59-72	adrenergic receptor, beta 2	Mus musculus	31-41
18174477-7	2008	RESULTS: Nortriptyline inhibits oxygen/glucose deprivation-induced cell death, loss of mitochondrial membrane potential, downstream release of mitochondrial factors, and activation of caspase 3 in primary cerebrocortical neurons.	Nortriptyline	9-22	caspase 3	Mus musculus	184-193
18280468-0	2008	Ecto-nucleotidase pathway is altered by different treatments with fluoxetine and nortriptyline.	Nortriptyline	81-94	tripartite motif containing 33	Homo sapiens	0-4
19441667-0	2008	[Association between polymorphisms of ins/del in the 5-HTT gene and T102C in the 5HTR2A gene and the drug response for escitalopram and nortriptyline in depressed patients].	Nortriptyline	136-149	solute carrier family 6 member 4	Homo sapiens	53-58
19441667-2	2008	The aim of this study was to find a possible association between polymorphisms of ins/del in the 5-HTT gene and T102C in the 5HTR2A gene and drug response for escitalopram and nortriptyline in depressed patients.	Nortriptyline	176-189	solute carrier family 6 member 4	Homo sapiens	97-102
19441668-0	2008	[Association between polymorphisms of Val66Met in the BDNF gene and the response to escitalopram and nortriptyline treatment in the light of the neurodevelopmental hypothesis of depression].	Nortriptyline	101-114	brain derived neurotrophic factor	Homo sapiens	54-58
17662092-9	2008	As a representative TCA, nortriptyline fulfilled the in vitro MBI criteria using recombinant CYP2C19 and CYP3A4 (K(I) and k(inact) values of 4 microm and 0.19 min(-1), and 70 microm and 0.06 min(-1)), but not with the human liver microsomal enzymes.	Nortriptyline	25-38	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	93-100
17662092-9	2008	As a representative TCA, nortriptyline fulfilled the in vitro MBI criteria using recombinant CYP2C19 and CYP3A4 (K(I) and k(inact) values of 4 microm and 0.19 min(-1), and 70 microm and 0.06 min(-1)), but not with the human liver microsomal enzymes.	Nortriptyline	25-38	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-111
17686041-8	2007	Furthermore, release of cytochrome c and activation of caspase 3, two molecular phenomena associated with mitochondrial-pathway-mediated cell death, were inhibited by nortriptyline.	Nortriptyline	167-180	caspase 3	Mus musculus	55-64
18057736-4	2007	The methods permit the determination of nortriptyline over a concentration range of 15-100 microg/ml and 5-24 microg/ml with the detection limit of 0.84 microg/ml and 0.32 microg/ml, using Nb-SCN and Fe-SCN, respectively.	Nortriptyline	40-53	sorcin	Homo sapiens	192-195
18057736-4	2007	The methods permit the determination of nortriptyline over a concentration range of 15-100 microg/ml and 5-24 microg/ml with the detection limit of 0.84 microg/ml and 0.32 microg/ml, using Nb-SCN and Fe-SCN, respectively.	Nortriptyline	40-53	sorcin	Homo sapiens	203-206
17944232-0	2007	[Influence of ORM1 polymorphism on serum concentration of free nortriptyline].	Nortriptyline	63-76	orosomucoid 1	Homo sapiens	14-18
17944232-1	2007	To study the effect of alpha1-acid glycoprotein 1 (ORM1) polymorphism on the concentration of free nortriptyline in serum, genotyping analysis was employed in ORM1 by sequencing.	Nortriptyline	99-112	orosomucoid 1	Homo sapiens	23-49
17944232-1	2007	To study the effect of alpha1-acid glycoprotein 1 (ORM1) polymorphism on the concentration of free nortriptyline in serum, genotyping analysis was employed in ORM1 by sequencing.	Nortriptyline	99-112	orosomucoid 1	Homo sapiens	51-55
17944232-8	2007	Different ORM1 genotypes might affect the protein binding percentage and the concentration of serum free nortriptyline.	Nortriptyline	105-118	orosomucoid 1	Homo sapiens	10-14
17944232-9	2007	The ability binding to the drug was higher in subjects with ORM1 * S/ * S genotype than in those with other two genotypes, so as to cause the lower concentration of free nortriptyline.	Nortriptyline	170-183	orosomucoid 1	Homo sapiens	60-64
17071817-0	2007	Inhibition of astroglial inwardly rectifying Kir4.1 channels by a tricyclic antidepressant, nortriptyline.	Nortriptyline	92-105	potassium inwardly rectifying channel subfamily J member 10	Homo sapiens	45-51
17592482-0	2007	c-Fos expression identifies brain areas activated in response to nortriptyline.	Nortriptyline	65-78	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	0-5
17071817-2	2007	We examined the effects of nortriptyline, a tricyclic antidepressant (TCA), on Kir4.1 channel currents heterologously expressed in HEK293T cells, using a whole-cell patch-clamp technique.	Nortriptyline	27-40	potassium inwardly rectifying channel subfamily J member 10	Homo sapiens	79-85
17071817-3	2007	Nortriptyline (3-300 microM) reversibly inhibited Kir4.1 currents in a concentration-dependent manner, whereas it marginally affected neuronal Kir2.1 currents.	Nortriptyline	0-13	potassium inwardly rectifying channel subfamily J member 10	Homo sapiens	50-56
17071817-4	2007	The inhibition of Kir4.1 channels by nortriptyline depended on the voltage difference from the K(+) equilibrium potential (E(K)), with greater potency at more positive potentials.	Nortriptyline	37-50	potassium inwardly rectifying channel subfamily J member 10	Homo sapiens	18-24
17071817-6	2007	The dissociation constant (K(d)) of nortriptyline for Kir4.1 inhibition was 28.1 microM at E(K).	Nortriptyline	36-49	potassium inwardly rectifying channel subfamily J member 10	Homo sapiens	54-60
17071817-8	2007	This study shows for the first time that nortriptyline and related TCAs cause a concentration-, voltage-, and time-dependent inhibition of astroglial K(+)-buffering Kir4.1 channels, which might be involved in therapeutic and/or adverse actions of the drugs.	Nortriptyline	41-54	potassium inwardly rectifying channel subfamily J member 10	Homo sapiens	165-171
16670375-4	2006	Mecp2 was not induced by repeated injections of 1-(2-bis(4-fluorphenyl)-methoxy)-ethyl)-4-(3-phenyl-propyl)piperazine (GBR-12909) or nortriptyline.	Nortriptyline	133-146	methyl CpG binding protein 2	Rattus norvegicus	0-5
15963243-5	2006	The exposure of mixed glial culture to amitriptyline and nortriptyline led to a decrease in both IL-1beta and TNF-alpha release.	Nortriptyline	57-70	interleukin 1 beta	Rattus norvegicus	97-105
15963243-3	2006	The aim of this study was to evaluate the effect of amitriptyline and its metabolite nortriptyline on the release of IL-1beta and TNF-alpha by lipopolysaccharide (LPS)-activated rat mixed glial and microglial cell cultures.	Nortriptyline	85-98	interleukin 1 beta	Rattus norvegicus	117-125
15963243-3	2006	The aim of this study was to evaluate the effect of amitriptyline and its metabolite nortriptyline on the release of IL-1beta and TNF-alpha by lipopolysaccharide (LPS)-activated rat mixed glial and microglial cell cultures.	Nortriptyline	85-98	tumor necrosis factor	Rattus norvegicus	130-139
16785274-5	2006	CYP2D6 genotypes predicted plasma steady state concentrations of nortriptyline, a classic DH substrate, in a sample of geriatric patients with major depression.	Nortriptyline	65-78	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
16778723-10	2006	In addition, the authors measured plasma concentrations of 16 healthy volunteers after administration of nortriptyline and identified the impact of the CYP2D6 genotype on nortriptyline metabolism.	Nortriptyline	171-184	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	152-158
16841511-0	2006	The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites.	Nortriptyline	74-87	phosphoglycolate phosphatase	Mus musculus	17-31
16841511-1	2006	The impact of P-glycoprotein (P-gp) on the distribution of nortriptyline (NT) and its metabolites between brain, liver and serum was studied experimentally.	Nortriptyline	59-72	phosphoglycolate phosphatase	Mus musculus	14-28
16841511-1	2006	The impact of P-glycoprotein (P-gp) on the distribution of nortriptyline (NT) and its metabolites between brain, liver and serum was studied experimentally.	Nortriptyline	59-72	phosphoglycolate phosphatase	Mus musculus	30-34
16841511-1	2006	The impact of P-glycoprotein (P-gp) on the distribution of nortriptyline (NT) and its metabolites between brain, liver and serum was studied experimentally.	Nortriptyline	74-76	phosphoglycolate phosphatase	Mus musculus	14-28
16841511-1	2006	The impact of P-glycoprotein (P-gp) on the distribution of nortriptyline (NT) and its metabolites between brain, liver and serum was studied experimentally.	Nortriptyline	74-76	phosphoglycolate phosphatase	Mus musculus	30-34
15963243-5	2006	The exposure of mixed glial culture to amitriptyline and nortriptyline led to a decrease in both IL-1beta and TNF-alpha release.	Nortriptyline	57-70	tumor necrosis factor	Rattus norvegicus	110-119
15963243-8	2006	Our study has shown for the first time that amitriptyline and nortriptyline administered at concentrations which may be achieved in plasma and brain structures during treatment, inhibit the secretion of IL-1beta and TNF-alpha in rat mixed glial and microglial cell cultures.	Nortriptyline	62-75	interleukin 1 beta	Rattus norvegicus	203-211
15963243-8	2006	Our study has shown for the first time that amitriptyline and nortriptyline administered at concentrations which may be achieved in plasma and brain structures during treatment, inhibit the secretion of IL-1beta and TNF-alpha in rat mixed glial and microglial cell cultures.	Nortriptyline	62-75	tumor necrosis factor	Rattus norvegicus	216-225
16175144-7	2005	CYP2D6 is an important intermediate enzyme in metabolism of amitriptyline to nortriptyline.	Nortriptyline	77-90	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
16275280-0	2005	The adsorption mechanism of nortryptiline on C18-bonded Discovery.	Nortriptyline	28-41	Bardet-Biedl syndrome 9	Homo sapiens	45-48
16841511-2	2006	The interaction of NT with P-gp in vitro was confirmed by measurement of P-gp stimulated ATPase activity (Km = 257.6 microM, Vmax = 51.0 nmol phosphate released/mg protein-min).	Nortriptyline	19-21	phosphoglycolate phosphatase	Mus musculus	27-31
16841511-2	2006	The interaction of NT with P-gp in vitro was confirmed by measurement of P-gp stimulated ATPase activity (Km = 257.6 microM, Vmax = 51.0 nmol phosphate released/mg protein-min).	Nortriptyline	19-21	phosphoglycolate phosphatase	Mus musculus	73-77
16841511-10	2006	The results show that P-gp influences the penetration of NT into the brain, and that drug-drug interactions may take place.	Nortriptyline	57-59	phosphoglycolate phosphatase	Mus musculus	22-26
16139174-5	2005	But nortriptyline repeatedly given 24, 5 and 1 h before behavioral tests significantly decreased an immobility time in FST without effects in motor activities, and showed weak brain MAO-B inhibition.	Nortriptyline	4-17	monoamine oxidase B	Homo sapiens	182-187
16118767-2	2005	Several psychotropic drugs, including nortriptyline (NT) and risperidone (Risp), are substrates of P-gp.	Nortriptyline	38-51	phosphoglycolate phosphatase	Mus musculus	99-103
16118767-2	2005	Several psychotropic drugs, including nortriptyline (NT) and risperidone (Risp), are substrates of P-gp.	Nortriptyline	53-55	phosphoglycolate phosphatase	Mus musculus	99-103
16118767-6	2005	When P-gp was inhibited with cyclosporine A (CsA) in Wistar rats, the effect was an order of magnitude less than that observed for the knock-out mice experiments (1-1.5 times the controls), and co-administration of NT had no effect.	Nortriptyline	215-217	phosphoglycolate phosphatase	Rattus norvegicus	5-9
16175144-8	2005	Nortriptyline is further metabolized to 10-hydroxy metabolites, mainly by CYP2D6.	Nortriptyline	0-13	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	74-80
15624117-0	2005	Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood-brain barrier.	Nortriptyline	91-104	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	13-27
15624117-8	2005	These results suggest that inhibition of P-gp by CsA increases the accumulation of NT in the brain.	Nortriptyline	83-85	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	41-45
15624117-10	2005	In conclusion, the results show that drug-drug interaction at P-gp may influence the intracerebral NT concentration, but apparently, a major inhibition of P-gp is necessary to attain a measurable effect.	Nortriptyline	99-101	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	62-66
15624117-10	2005	In conclusion, the results show that drug-drug interaction at P-gp may influence the intracerebral NT concentration, but apparently, a major inhibition of P-gp is necessary to attain a measurable effect.	Nortriptyline	99-101	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	155-159
15304522-4	2004	Spectral scanning of recombinant CYP2C8 demonstrated the formation of metabolite-intermediate complexes with verapamil, nortriptyline, fluoxetine, and isoniazid, but not amiodarone.	Nortriptyline	120-133	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	33-39
15483356-0	2004	A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication.	Nortriptyline	82-95	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	39-45
15483356-1	2004	We present a case with decreased metabolic activity of CYP2D6, a cytochrome P450 enzyme catalyzing the metabolism of nortriptyline (NT).	Nortriptyline	117-130	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	55-61
15483356-1	2004	We present a case with decreased metabolic activity of CYP2D6, a cytochrome P450 enzyme catalyzing the metabolism of nortriptyline (NT).	Nortriptyline	132-134	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	55-61
15483356-2	2004	Conventional dosage regimen led to toxic plasma concentration of NT and adverse effects such as dry mouth, constipation, and dizziness in this case with genotype CYP2D6*5/*10B.	Nortriptyline	65-67	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	162-168
15180333-14	2004	The VizStruct visualization succinctly summarized the salient similarities and differences in the nortriptyline and 10-hydroxynortriptyline pharmacokinetic profiles in subjects with increasing number of CYP2D6 gene copies.	Nortriptyline	98-111	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	203-209
15205367-0	2004	Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.	Nortriptyline	142-155	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	159-166
15205367-0	2004	Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.	Nortriptyline	142-155	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	171-177
15205367-5	2004	RESULTS: Eighteen CYP2C19 heterozygotes (*1/*2) had higher AT (P = 0.033) and lower nortriptyline (NT; P = 0.059) concentrations than 30 homozygotes (*1/*1).	Nortriptyline	84-97	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	18-25
15150531-4	2004	Here, we report the inhibitory effects of various antidepressants: imipramine, desipramine, amitriptyline, nortriptyline, clomipramine, maprotiline, and citalopram, on GIRK channels.	Nortriptyline	107-120	potassium inwardly rectifying channel subfamily J member 3 S homeolog	Xenopus laevis	168-172
14604448-0	2003	Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline.	Nortriptyline	162-175	solute carrier family 6 member 4	Homo sapiens	68-89
14716707-1	2004	The polymorphic enzyme cytochrome P450 CYP2D6 is involved in the metabolism of many antidepressants, including nortriptyline and fluoxetine.	Nortriptyline	111-124	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	39-45
14716707-5	2004	This paper explores the link between CYP2D6 genotype and antidepressant-associated ADRs in outpatients being treated for major depression with either nortriptyline or fluoxetine.	Nortriptyline	150-163	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	37-43
14604448-0	2003	Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline.	Nortriptyline	162-175	G protein subunit beta 3	Homo sapiens	94-109
14604448-2	2003	For depressed patients under the age of 25 yr the T allele of the G protein beta3 subunit was associated with a markedly poorer response to nortriptyline, while serotonin transporter polymorphisms did not predict antidepressant response.	Nortriptyline	140-153	G protein subunit beta 3	Homo sapiens	66-81
14604448-3	2003	However, in patients 25 yr or older, the G protein beta3 polymorphisms did not predict antidepressant response, while the s,s genotype of the serotonin transporter was associated with a poorer response to both fluoxetine and nortriptyline.	Nortriptyline	225-238	solute carrier family 6 member 4	Homo sapiens	142-163
12398564-6	2002	DISCUSSION: Metabolism by CYP2D6 is of major importance for the hydroxylation of nortriptyline, making it susceptible to competitive inhibition by terbinafine.	Nortriptyline	81-94	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	26-32
12814461-0	2003	Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians.	Nortriptyline	32-45	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	80-86
12814461-1	2003	AIMS: To study the influence of the CYP2D6*10 allele on the disposition of debrisoquine and nortriptyline.	Nortriptyline	92-105	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	36-42
12814461-9	2003	CONCLUSIONS: Heterozygosity for CYP2D6*10 decreases the CYP2D6-dependent elimination of nortriptyline and debrisoquine to only a limited degree.	Nortriptyline	88-101	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	32-38
12814461-9	2003	CONCLUSIONS: Heterozygosity for CYP2D6*10 decreases the CYP2D6-dependent elimination of nortriptyline and debrisoquine to only a limited degree.	Nortriptyline	88-101	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	56-62
14555335-9	2003	The secondary amines nisoxetine (NIS), and especially, desipramine (DES) and nortriptyline (NOR), also inhibited CYP2C11 and generated MI complexes with microsomal CYP.	Nortriptyline	77-90	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	113-120
14555335-9	2003	The secondary amines nisoxetine (NIS), and especially, desipramine (DES) and nortriptyline (NOR), also inhibited CYP2C11 and generated MI complexes with microsomal CYP.	Nortriptyline	77-90	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	113-116
14555335-9	2003	The secondary amines nisoxetine (NIS), and especially, desipramine (DES) and nortriptyline (NOR), also inhibited CYP2C11 and generated MI complexes with microsomal CYP.	Nortriptyline	92-95	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	113-120
14555335-9	2003	The secondary amines nisoxetine (NIS), and especially, desipramine (DES) and nortriptyline (NOR), also inhibited CYP2C11 and generated MI complexes with microsomal CYP.	Nortriptyline	92-95	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	113-116
12398564-7	2002	CONCLUSIONS: The pharmacokinetic interaction between nortriptyline and terbinafine is probably due to inhibition of CYP2D6 of the nortriptyline metabolism by terbinafine.	Nortriptyline	53-66	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	116-122
12398564-7	2002	CONCLUSIONS: The pharmacokinetic interaction between nortriptyline and terbinafine is probably due to inhibition of CYP2D6 of the nortriptyline metabolism by terbinafine.	Nortriptyline	130-143	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	116-122
12380814-2	2002	For example, retention factor values, k, obtained from protonated nordoxepin, nortriptyline, and amitriptyline increase almost 1 order of magnitude across the following series of anions employed as mobile-phase modifiers: H2PO4- < HCOO- < CH3SO3- < Cl- < NO3- < CF3COO- < BF4- < ClO4- < PF6-.	Nortriptyline	78-91	NBL1, DAN family BMP antagonist	Homo sapiens	267-270
12380814-2	2002	For example, retention factor values, k, obtained from protonated nordoxepin, nortriptyline, and amitriptyline increase almost 1 order of magnitude across the following series of anions employed as mobile-phase modifiers: H2PO4- < HCOO- < CH3SO3- < Cl- < NO3- < CF3COO- < BF4- < ClO4- < PF6-.	Nortriptyline	78-91	sperm associated antigen 17	Homo sapiens	311-314
11682257-2	2001	The CYP2D6 gene encodes debrisoquine hydroxylase, which metabolizes the antidepressant nortriptyline and other psychotropic medications.	Nortriptyline	87-100	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	4-10
12082591-0	2002	A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression.	Nortriptyline	56-69	ATP binding cassette subfamily B member 1	Homo sapiens	9-23
12082591-2	2002	The antidepressant amitriptyline and its metabolites (including nortriptyline) are substrates for P-gp, and in mice lacking P-gp, penetration of amitriptyline, but not fluoxetine, into the brain is enhanced.	Nortriptyline	64-77	phosphoglycolate phosphatase	Mus musculus	98-102
12082591-6	2002	Our results suggest that homozygosity for 3435T alleles of ABCB1 is a risk factor for occurrence of nortriptyline-induced postural hypotension (OR = 1.37, P = 0.042, 95% CI 1.01-1.86).	Nortriptyline	100-113	ATP binding cassette subfamily B member 1	Homo sapiens	59-64
12352271-0	2002	Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients.	Nortriptyline	10-23	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	42-48
12352271-1	2002	This study was performed in elderly patients (1) to assess the degree to which CYP2D6 mediated metabolism of debrisoquine at baseline determines plasma concentration to dose quotients for nortriptyline or paroxetine after 4 weeks of treatment, and (2) to compare the effects of nortriptyline and paroxetine on debrisoquine metabolism after 6 weeks of treatment.	Nortriptyline	188-201	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	79-85
12352271-1	2002	This study was performed in elderly patients (1) to assess the degree to which CYP2D6 mediated metabolism of debrisoquine at baseline determines plasma concentration to dose quotients for nortriptyline or paroxetine after 4 weeks of treatment, and (2) to compare the effects of nortriptyline and paroxetine on debrisoquine metabolism after 6 weeks of treatment.	Nortriptyline	278-291	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	79-85
12352271-6	2002	Treatment with either nortriptyline or paroxetine was associated with a significant decrease in the median debrisoquine recovery ratio, reflecting inhibition of CYP2D6 metabolism.	Nortriptyline	22-35	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	161-167
12352271-10	2002	The significant correlations between baseline debrisoquine recovery ratio and the plasma concentrations to dose quotients at 4 weeks for both nortriptyline and paroxetine are consistent with CYP2D6 playing a major role in the metabolism of both drugs.	Nortriptyline	142-155	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	191-197
11588102-13	2001	There is also structural similarity between non-competitive and competitive inhibitors, e.g., phloretin is the aglycone of phlorizin (hSGLT1) and nortriptyline resembles SKF89976A without nipecotic acid (hGAT1).	Nortriptyline	146-159	solute carrier family 6 member 1	Homo sapiens	204-209
10770451-0	2000	Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline.	Nortriptyline	149-162	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	109-115
11673748-0	2001	Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.	Nortriptyline	121-134	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	14-32
10872574-3	2000	So, this study was carried out to determine the concentrations of AMT and its demethylated metabolite, nortriptyline (NTR), after acute single oral administration of AMT in rats.	Nortriptyline	103-116	aminomethyltransferase	Rattus norvegicus	166-169
11735606-11	2001	Using the frequency distribution of CYP2D6 genotype with the above results we estimate that, in compliant Swedish individuals on nortriptyline monotherapy, the number of functional CYP2D6 genes could explain 21% of the total interindividual variance in oral clearance of nortriptyline and 34% of that in steady-state plasma concentrations.	Nortriptyline	129-142	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	36-42
11735606-11	2001	Using the frequency distribution of CYP2D6 genotype with the above results we estimate that, in compliant Swedish individuals on nortriptyline monotherapy, the number of functional CYP2D6 genes could explain 21% of the total interindividual variance in oral clearance of nortriptyline and 34% of that in steady-state plasma concentrations.	Nortriptyline	129-142	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	181-187
11735606-11	2001	Using the frequency distribution of CYP2D6 genotype with the above results we estimate that, in compliant Swedish individuals on nortriptyline monotherapy, the number of functional CYP2D6 genes could explain 21% of the total interindividual variance in oral clearance of nortriptyline and 34% of that in steady-state plasma concentrations.	Nortriptyline	271-284	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	36-42
11735606-11	2001	Using the frequency distribution of CYP2D6 genotype with the above results we estimate that, in compliant Swedish individuals on nortriptyline monotherapy, the number of functional CYP2D6 genes could explain 21% of the total interindividual variance in oral clearance of nortriptyline and 34% of that in steady-state plasma concentrations.	Nortriptyline	271-284	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	181-187
10770451-1	2000	The authors investigated the impact of the CYP2D6 genotype on steady-state concentrations of nortriptyline (NT) and its metabolites, trans-10-hydroxynortriptyline (EHNT) and cis-10-hydroxynortriptyline in a Japanese population of psychiatric patients.	Nortriptyline	93-106	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	43-49
9867310-3	1998	The main probe drugs include caffeine and theophylline, whose metabolism is catalysed by CYP1A2, tolbutamide, phenytoin and ibuprofen, catalysed by CYP2C9, amitriptyline and nortriptyline, catalysed by CYP2C19, acetaminophen, catalysed by CYP2E1 and lidocaine, midazolam and terfenadine, catalysed by 3A3/4.	Nortriptyline	174-187	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	89-95
9797795-0	1998	Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes.	Nortriptyline	20-33	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	97-103
9797795-1	1998	OBJECTIVES: To study the impact of the CYP2D6*10 allele on the disposition of nortriptyline in Chinese subjects.	Nortriptyline	78-91	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	39-45
9797795-5	1998	RESULTS: Subjects who were homozygous for CYP2D6*10 had significantly higher total areas under the plasma concentration-time curve (AUC), lower apparent oral clearances, and longer mean plasma half-life of nortriptyline than subjects in the CYP2D6*1/*1 and the heterozygous groups.	Nortriptyline	206-219	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	42-48
9797795-7	1998	CONCLUSION: The CYP2D6*10 allele in Chinese subjects was associated with significantly higher plasma levels of nortriptyline compared with the CYP2D6*1 allele because of an impaired metabolism of nortriptyline to 10-hydroxynortriptyline, particularly in the subjects with the CYP2D6*10/*10 genotype.	Nortriptyline	111-124	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	16-22
9797795-7	1998	CONCLUSION: The CYP2D6*10 allele in Chinese subjects was associated with significantly higher plasma levels of nortriptyline compared with the CYP2D6*1 allele because of an impaired metabolism of nortriptyline to 10-hydroxynortriptyline, particularly in the subjects with the CYP2D6*10/*10 genotype.	Nortriptyline	196-209	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	16-22
9797795-7	1998	CONCLUSION: The CYP2D6*10 allele in Chinese subjects was associated with significantly higher plasma levels of nortriptyline compared with the CYP2D6*1 allele because of an impaired metabolism of nortriptyline to 10-hydroxynortriptyline, particularly in the subjects with the CYP2D6*10/*10 genotype.	Nortriptyline	196-209	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	143-149
9797795-7	1998	CONCLUSION: The CYP2D6*10 allele in Chinese subjects was associated with significantly higher plasma levels of nortriptyline compared with the CYP2D6*1 allele because of an impaired metabolism of nortriptyline to 10-hydroxynortriptyline, particularly in the subjects with the CYP2D6*10/*10 genotype.	Nortriptyline	196-209	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	143-149
9797795-8	1998	The results suggest that genotyping of CYP2D6 may be a useful tool in predicting the pharmacokinetics of nortriptyline.	Nortriptyline	105-118	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	39-45
10379421-6	1999	Both amitriptyline and nortriptyline are also 5-HT2 receptor antagonists.	Nortriptyline	23-36	5-hydroxytryptamine receptor 2A	Homo sapiens	46-60
10354960-0	1999	Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.	Nortriptyline	0-13	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	63-69
10354960-0	1999	Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.	Nortriptyline	0-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-96
10354960-7	1999	A simulation of the relative contribution of CYPs 2D6 and 3A4 to net nortriptyline hydroxylation rate suggested that the relative contribution of CYP3A4 is only 20% even at the higher end of the therapeutic range.	Nortriptyline	69-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	146-152
10354960-9	1999	The identification of CYP3A4 as a low-affinity nortriptyline E-10-hydroxylase explains the ability of poor metabolizers of debrisoquin to hydroxylate nortriptyline, as well as the increased in vivo clearance via this pathway caused by CYP3A4-inducing drugs such as pentobarbital, carbamazepine, and rifampin.	Nortriptyline	47-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	22-28
10354960-9	1999	The identification of CYP3A4 as a low-affinity nortriptyline E-10-hydroxylase explains the ability of poor metabolizers of debrisoquin to hydroxylate nortriptyline, as well as the increased in vivo clearance via this pathway caused by CYP3A4-inducing drugs such as pentobarbital, carbamazepine, and rifampin.	Nortriptyline	47-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	235-241
9867310-3	1998	The main probe drugs include caffeine and theophylline, whose metabolism is catalysed by CYP1A2, tolbutamide, phenytoin and ibuprofen, catalysed by CYP2C9, amitriptyline and nortriptyline, catalysed by CYP2C19, acetaminophen, catalysed by CYP2E1 and lidocaine, midazolam and terfenadine, catalysed by 3A3/4.	Nortriptyline	174-187	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	148-154
9585799-10	1998	CONCLUSION: The results of this study show the quantitative importance of the CYP2D6 genotype, especially the presence of multiple functional CYP2D6 genes for the pharmacokinetics of nortriptyline and 10-hydroxynortriptyline.	Nortriptyline	183-196	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	78-84
9585799-10	1998	CONCLUSION: The results of this study show the quantitative importance of the CYP2D6 genotype, especially the presence of multiple functional CYP2D6 genes for the pharmacokinetics of nortriptyline and 10-hydroxynortriptyline.	Nortriptyline	183-196	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	142-148
9549641-2	1998	Amitriptyline was N-demethylated to nortriptyline by microsomes from cDNA transfected human lymphoblastoid cells expressing human CYPs 1A2, 2C9, 2C19, 2D6, and 3A4.	Nortriptyline	36-49	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	130-143
9519934-4	1998	In the patients with depression, 5 months of treatment with imipramine and/or nortriptyline significantly reduced EPO concentrations in the CSF (1.56+/-0.34 mU/ mL, P < 0.01).	Nortriptyline	78-91	erythropoietin	Homo sapiens	114-117
9193876-1	1997	The metabolism of nortriptyline was studied in vitro using cDNA-expressed human cytochrome P450 isozymes 1A2, 3A4, 2C19, and 2D6, CYP2D6 was the sole isozyme mediating hydroxylation of nortriptyline, the quantitatively most important metabolic pathway, and only (E)-10-OH-nortriptyline was formed.	Nortriptyline	18-31	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	130-136
9220124-3	1997	This review article will focus on basic pharmacokinetic considerations for elderly patients when psychotropics metabolized by CYP2D6, such as nortriptyline and desipramine, are prescribed.	Nortriptyline	142-155	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	126-132
9220124-12	1997	Significant correlations have been reported between individual CYP2D6 activity and plasma concentrations of nortriptyline and desipramine.	Nortriptyline	108-121	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	63-69
9193876-0	1997	Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes.	Nortriptyline	64-77	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-118
9585799-0	1998	10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes.	Nortriptyline	20-33	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	86-92
9193876-2	1997	CYP2D6, 2C19, and 1A2, mentioned in decreasing order of significance, mediated the demethylation reaction of nortriptyline, whereas 3A4 did not participate in the metabolism of nortriptyline.	Nortriptyline	109-122	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
9193876-7	1997	In subjects lacking the 2D6 isozyme, CYP2C19 and 1A2 are expected to be of major importance for elimination of nortriptyline.	Nortriptyline	111-124	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	37-44
9131945-6	1997	The addition of quinidine, a selective inhibitor of CYP2D6, along with triacetyloleandomycin and sulphaphenazole produced an additional decrease in the rate of NT formation in all but the PM liver, but did not completely eliminate the reaction.	Nortriptyline	160-162	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	52-58
9169301-3	1997	In this study, the influence of the selective beta 1- (CGP 20712A) and beta 2- (ICI 118551) adrenergic blockers on the antinociceptive effect of desipramine and nortriptyline was studied in mice using physical and chemical nociceptive tests that implicate different levels of sensory-motor integration in the central nervous system (CNS).	Nortriptyline	161-174	hemoglobin, beta adult major chain	Mus musculus	46-52
9169301-3	1997	In this study, the influence of the selective beta 1- (CGP 20712A) and beta 2- (ICI 118551) adrenergic blockers on the antinociceptive effect of desipramine and nortriptyline was studied in mice using physical and chemical nociceptive tests that implicate different levels of sensory-motor integration in the central nervous system (CNS).	Nortriptyline	161-174	hemoglobin, beta adult minor chain	Mus musculus	71-77
8867869-0	1996	Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype.	Nortriptyline	30-43	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	95-101
9041677-3	1997	It was established that CYP2D6 not only catalyzed ring 10-hydroxylation of AMI, but also mediated its N-demethylation to nortriptyline (NT), as well as the formation of 10-hydroxy-NT from NT.	Nortriptyline	121-134	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	24-30
9041677-3	1997	It was established that CYP2D6 not only catalyzed ring 10-hydroxylation of AMI, but also mediated its N-demethylation to nortriptyline (NT), as well as the formation of 10-hydroxy-NT from NT.	Nortriptyline	136-138	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	24-30
9041677-3	1997	It was established that CYP2D6 not only catalyzed ring 10-hydroxylation of AMI, but also mediated its N-demethylation to nortriptyline (NT), as well as the formation of 10-hydroxy-NT from NT.	Nortriptyline	180-182	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	24-30
8842678-4	1996	Both the A-form (MAO-A) and B-form (MAO-B) of MAO were inhibited after long-term administration of all the drugs except nortriptyline (MAO-A was not affected) and maprotiline (neither MAO-A nor MAO-B were affected).	Nortriptyline	120-133	monoamine oxidase A	Mus musculus	17-22
8842678-4	1996	Both the A-form (MAO-A) and B-form (MAO-B) of MAO were inhibited after long-term administration of all the drugs except nortriptyline (MAO-A was not affected) and maprotiline (neither MAO-A nor MAO-B were affected).	Nortriptyline	120-133	monoamine oxidase B	Mus musculus	36-41
8842678-10	1996	MAO-A was inhibited by the following drugs (in ascending order of potency) : nortriptyline, amitriptyline, imipramine, maprotiline, zimeldine, nomifensine, and viloxazine.	Nortriptyline	77-90	monoamine oxidase A	Mus musculus	0-5
8842678-12	1996	MAO-B was inhibited by the following drugs (in ascending order of potency): nortriptyline, imipramine, maprotiline, amitriptyline, zimeldine, nomifensine, and viloxazine.	Nortriptyline	76-89	monoamine oxidase B	Mus musculus	0-5
8661340-1	1996	The commonly used antidepressants imipramine, amitriptyline, and nortriptyline were found to significantly inhibit human natural killer (NK) cell-mediated cytolysis in vitro and suppress the stimulation of NK cells by IFN-gamma.	Nortriptyline	65-78	interferon gamma	Homo sapiens	218-227
8867869-1	1996	The relationship between the CYP2D6 genotype and the steady state plasma levels of nortriptyline (NT), its main active metabolite 10-hydroxynortriptyline (10-OH-NT) and the NT/10-OH-NT ratio were studied in 21 Caucasian depressed patients treated with 100-150 mg NT daily.	Nortriptyline	83-96	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	29-35
8867869-9	1996	The present follow-up study confirms a relationship between the CYP2D6 genotype and the plasma levels of NT and its active metabolite.	Nortriptyline	105-107	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	64-70
8866640-4	1996	RESULTS: The average plasma concentration of nortriptyline at steady state (Css) divided by the amount of nortriptyline administered per time rose significantly in a patient with concomitant administration of diltiazem, suggesting increased bioavailability and/or decreased clearance of nortriptyline.	Nortriptyline	45-58	cytidine monophosphate N-acetylneuraminic acid synthetase	Homo sapiens	76-79
7893588-0	1994	Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method.	Nortriptyline	31-44	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	121-127
7893588-4	1994	This may be explained by the recent discovery of subjects with multiple copies of the gene encoding the cytochrome-P450-enzyme CYP2D6, which catalyses the hydroxylation of nortriptyline.	Nortriptyline	172-185	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	127-133
7893588-7	1994	Concomitant therapy with drugs that inhibit CYP2D6 resulted in a major increase in the plasma nortriptyline concentrations.	Nortriptyline	94-107	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	44-50
8005189-8	1994	The metabolism of nortriptyline has been shown to be partly dependent on the debrisoquine hydroxylase CYP2D6.	Nortriptyline	18-31	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	102-108
7909176-7	1994	Intraindividual comparisons of the ratio C/D in subjects with analyses performed when off and on concomitant drugs corroborate previous results showing that drugs metabolized by the debrisoquine hydroxylase (CYP2D6) inhibit the metabolism of NT and that carbamazepine induces the metabolism of both AT and NT.	Nortriptyline	242-244	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	208-214
7909176-7	1994	Intraindividual comparisons of the ratio C/D in subjects with analyses performed when off and on concomitant drugs corroborate previous results showing that drugs metabolized by the debrisoquine hydroxylase (CYP2D6) inhibit the metabolism of NT and that carbamazepine induces the metabolism of both AT and NT.	Nortriptyline	306-308	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	208-214
6397777-5	1984	Nortriptyline administered for three weeks to healthy volunteers, pretreated with dexamethasone, increased insulin sensitivity.	Nortriptyline	0-13	insulin	Homo sapiens	107-114
35118877-4	2022	Results: CYP2C19 metabolizer status explained interpatient variation in nortriptyline to amitriptyline concentration ratios.	Nortriptyline	72-85	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	9-16
35118877-6	2022	In patients at high CYP2D6 inhibition risk, the amitriptyline + nortriptyline concentration was, on average, 52% above the higher end of expected ranges.	Nortriptyline	64-77	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	20-26
2541855-6	1989	The effects of nortriptyline, amineptine, maprotiline, nomifensine and mianserin, but not that of clomipramine, were potentiated by TRH (2 mg kg-1, i.p.).	Nortriptyline	15-28	thyrotropin releasing hormone	Mus musculus	132-135
3703101-1	1986	Antiserum to nortriptyline was generated in male New Zealand rabbits innoculated with n-succinylnortriptyline-bovine serum albumin conjugates.	Nortriptyline	13-26	albumin	Oryctolagus cuniculus	117-130
8509652-3	1993	Amitriptyline and nortriptyline were structurally modified by the attachment of spacer arms to the aromatic ring which were subsequently attached to bovine serum albumin (BSA).	Nortriptyline	18-31	albumin	Oryctolagus cuniculus	156-169
7855185-1	1993	The CSF/plasma ratios of nortriptyline (NT) and its major metabolite 10-hydroxy-NT (10-OH-NT) were investigated retrospectively in 25 depressed patients.	Nortriptyline	25-38	colony stimulating factor 2	Homo sapiens	4-7
1435757-0	1992	Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline.	Nortriptyline	93-106	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	51-71
1858301-0	1991	Effects of alpha-1-acid glycoprotein on the cardiovascular toxicity of nortriptyline in a swine model.	Nortriptyline	71-84	alpha-1-acid glycoprotein	Sus scrofa	11-36
1858301-2	1991	This trial investigated the effect of alpha-1-acid glycoprotein (AAG), an acute phase reactant with a high affinity for basic drugs, on the clinical and pharmacological manifestations of nortriptyline (NT) toxicity.	Nortriptyline	187-200	alpha-1-acid glycoprotein	Sus scrofa	38-63
1858301-2	1991	This trial investigated the effect of alpha-1-acid glycoprotein (AAG), an acute phase reactant with a high affinity for basic drugs, on the clinical and pharmacological manifestations of nortriptyline (NT) toxicity.	Nortriptyline	187-200	alpha-1-acid glycoprotein	Sus scrofa	65-68
1858301-2	1991	This trial investigated the effect of alpha-1-acid glycoprotein (AAG), an acute phase reactant with a high affinity for basic drugs, on the clinical and pharmacological manifestations of nortriptyline (NT) toxicity.	Nortriptyline	202-204	alpha-1-acid glycoprotein	Sus scrofa	38-63
1858301-2	1991	This trial investigated the effect of alpha-1-acid glycoprotein (AAG), an acute phase reactant with a high affinity for basic drugs, on the clinical and pharmacological manifestations of nortriptyline (NT) toxicity.	Nortriptyline	202-204	alpha-1-acid glycoprotein	Sus scrofa	65-68
2306263-3	1990	This antibody was not similar in binding properties to polyclonal antisera produced using the same antigen but was highly similar in binding properties to a monoclonal anti-nortriptyline antibody, ANT3, raised by Marulo et al.	Nortriptyline	173-186	solute carrier family 25 member 6	Homo sapiens	197-201
34609966-9	2021	In a drug screen that targeted RBMS1, we further uncovered that nortriptyline hydrochloride decreased the level of RBMS1, thereby promoting ferroptosis.	Nortriptyline	64-91	RNA binding motif single stranded interacting protein 1	Homo sapiens	31-36
34609966-9	2021	In a drug screen that targeted RBMS1, we further uncovered that nortriptyline hydrochloride decreased the level of RBMS1, thereby promoting ferroptosis.	Nortriptyline	64-91	RNA binding motif single stranded interacting protein 1	Homo sapiens	115-120
34609966-10	2021	Importantly, RBMS1 depletion or inhibition by nortriptyline hydrochloride sensitized radioresistant lung cancer cells to radiotherapy.	Nortriptyline	46-73	RNA binding motif single stranded interacting protein 1	Homo sapiens	13-18
34464602-5	2021	The main results in adolescent rats showed that nortriptyline induced dose-dependent opposite effects: while 3 mg/kg decreased immobility and increased mBDNF (indicative of an antidepressant-like response), 10 mg/kg decreased exploratory time in the open field and mBDNF (suggestive of an anxiogenic-like response).	Nortriptyline	48-61	brain derived neurotrophic factor	Mus musculus	152-157
34464602-5	2021	The main results in adolescent rats showed that nortriptyline induced dose-dependent opposite effects: while 3 mg/kg decreased immobility and increased mBDNF (indicative of an antidepressant-like response), 10 mg/kg decreased exploratory time in the open field and mBDNF (suggestive of an anxiogenic-like response).	Nortriptyline	48-61	brain derived neurotrophic factor	Mus musculus	265-270
34093211-3	2021	Here, the impact of OCT1 genetic variation on the pharmacokinetics of amitriptyline and its active metabolite nortriptyline was studied in vitro as well as in healthy volunteers and in depressive disorder patients.	Nortriptyline	110-123	solute carrier family 22 member 1	Homo sapiens	20-24
34093211-4	2021	Amitriptyline and nortriptyline were found to inhibit OCT1 in recombinant cells with IC50 values of 28.6 and 40.4 microM.	Nortriptyline	18-31	solute carrier family 22 member 1	Homo sapiens	54-58
2861702-7	1985	Endotoxin given after nortriptyline administration resulted in the increase of VIP levels regularly seen during endotoxinaemia.	Nortriptyline	22-35	vasoactive intestinal peptide	Homo sapiens	79-82
7428796-6	1980	It was possible to detect DTS for 228-300 h after the last oral dose and the mean Pd1/2 of this decline of pharmacodynamic effect was observed to be 135 h. However, no measurable amount of AT or NT was present after 84 h and the mean elimination plasma half-life (t1/2) of AT and NT were 37.7 and 38.9 h, respectively.	Nortriptyline	280-282	programmed cell death 1	Homo sapiens	82-87
6397777-0	1984	Effects of lithium, nortriptyline and dexamethasone on insulin sensitivity.	Nortriptyline	20-33	insulin	Homo sapiens	55-62
6272818-10	1981	At even higher concentrations of amitriptyline, nortriptyline or imipramine with spin label 616, however, no significant change of order parameter was observed indicating that perturbation of the hydrophobic membrane interior is not sensed.	Nortriptyline	48-61	spindlin 1	Homo sapiens	81-85
6418677-0	1983	Nortriptyline plasma levels and clinical response in patients with familial pure unipolar depression and blunted TRH tests.	Nortriptyline	0-13	thyrotropin releasing hormone	Homo sapiens	113-116
7105623-8	1982	Dialysis clearance of conjugated 10-hydroxynortriptyline was 58 +/- 8 (SD) ml min-1, but nortriptyline and unconjugated 10-hydroxynortriptyline were not appreciably removed by dialysis.	Nortriptyline	43-56	CD59 molecule (CD59 blood group)	Homo sapiens	78-83
6254586-1	1980	Thyrotropin releasing hormone (TRH) causes hyperthermia in mice which is potentiated by tricyclic antidepressants (nortriptyline, imipramine, clomipramine, amitriptyline), the monoamine oxidase inhibitor, tranylcypromine, and various other antidepressants (maprotiline, nomifensin, viloxazine).	Nortriptyline	115-128	thyrotropin releasing hormone	Mus musculus	0-29
34001114-9	2021	In FAERS, the strongest associations were found for nortriptyline (reporting odds ratio [ROR] 1.94, 95% CI 1.73-2.16), sucralfate (ROR 1.22, 95% CI 1.01-1.45), doxycycline (ROR 1.30, 95% CI 1.20-1.40), and hydroxyzine (ROR 1.17, 95% CI 1.06-1.29).	Nortriptyline	52-65	receptor tyrosine kinase like orphan receptor 1	Homo sapiens	173-178
8818-2	1976	Nortriptyline and protriptyline, antidepressant compounds which like NMT contain a secondary amino group, also serve as substrates for INMT but lack in inhibitory effect on DMT formation.	Nortriptyline	0-13	indolethylamine N-methyltransferase	Oryctolagus cuniculus	135-139
7366815-0	1980	Plasma prolactin during treatment with nortriptyline.	Nortriptyline	39-52	prolactin	Homo sapiens	7-16
7366815-5	1980	The results indicate that nortriptyline does not belong to the group of psychotropics which produce considerable increases in the plasma concentration of prolactin.	Nortriptyline	26-39	prolactin	Homo sapiens	154-163
34001114-9	2021	In FAERS, the strongest associations were found for nortriptyline (reporting odds ratio [ROR] 1.94, 95% CI 1.73-2.16), sucralfate (ROR 1.22, 95% CI 1.01-1.45), doxycycline (ROR 1.30, 95% CI 1.20-1.40), and hydroxyzine (ROR 1.17, 95% CI 1.06-1.29).	Nortriptyline	52-65	receptor tyrosine kinase like orphan receptor 1	Homo sapiens	173-178
32621544-1	2021	The antidepressant nortriptyline is metabolized by cytochrome P450 2D6 (CYP2D6) to the less active and more cardiotoxic drug metabolite, 10-hydroxynortriptyline.	Nortriptyline	19-32	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	51-70
33753003-8	2021	RESULTS: The CYP2C19 polymorphism exhibited a significant influence on the NT serum concentration but did not predict the clinical efficacy of AMT for treating IBS-D.	Nortriptyline	75-77	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	13-20
32621544-1	2021	The antidepressant nortriptyline is metabolized by cytochrome P450 2D6 (CYP2D6) to the less active and more cardiotoxic drug metabolite, 10-hydroxynortriptyline.	Nortriptyline	19-32	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	72-78
33421720-9	2021	We consistently observed a significant reduction in AChE activity in the animals exposed to 500 microg/L NTP.	Nortriptyline	105-108	acetylcholinesterase	Danio rerio	52-56
31738228-0	2020	A functional polymorphism in the ATP-Binding Cassette B1 transporter predicts pharmacologic response to combination of nortriptyline and morphine in neuropathic pain patients.	Nortriptyline	119-132	ATP binding cassette subfamily B member 1	Homo sapiens	33-68
32751911-5	2020	Negr1 was down-regulated by escitalopram in the hypothalamus of FSL rats, by fluoxetine in the hippocampal dentate gyrus of corticosterone-treated mice, and by nortriptyline in hippocampal primary neurons.	Nortriptyline	160-173	neuronal growth regulator 1	Rattus norvegicus	0-5
32751911-6	2020	Adam10 mRNA was increased by nortriptyline administration in the hypothalamus, by escitalopram in the hippocampus of FSL rats, and by fluoxetine in mouse dorsal dentate gyrus.	Nortriptyline	29-42	ADAM metallopeptidase domain 10	Rattus norvegicus	0-6
32751911-7	2020	Similarly, nortriptyline increased Adam10 expression in hippocampal cultures.	Nortriptyline	11-24	a disintegrin and metallopeptidase domain 10	Mus musculus	35-41
32751911-8	2020	Fgfr2 expression was increased by nortriptyline in the hypothalamus of FSL rats and in hippocampal neurons.	Nortriptyline	34-47	fibroblast growth factor receptor 2	Rattus norvegicus	0-5
31738228-7	2020	However, for nortriptyline + morphine combination therapy, the single nucleotide polymorphism rs1045642 within the drug efflux pump ABCB1 transporter significantly predicted analgesic response.	Nortriptyline	13-26	ATP binding cassette subfamily B member 1	Homo sapiens	132-137
31882254-8	2020	There were significantly lower frequencies of CD8+ T-cells after treatment with amitriptyline, nortriptyline and a combination of both compared to a Vehicle Control(VC)(p<0.001).	Nortriptyline	95-108	CD8a molecule	Homo sapiens	46-49
31882254-9	2020	The frequencies of naive CD8+CD45RA+ cells were significantly lower after amitriptyline, nortriptyline and a combination of both (p<0001).	Nortriptyline	89-102	CD8a molecule	Homo sapiens	25-28
31770580-1	2020	The beta-CD encapsulation of two tricyclic antidepressants (TCAs), nortriptyline (NRT) HCl and amitriptyline (AMT) HCl (most widely used TCA), has been thoroughly investigated by single-crystal X-ray diffraction and DFT calculation for insights into the inclusion complexation.	Nortriptyline	67-80	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	4-11
30452773-11	2019	Production of nortriptyline from amitriptyline was associated with CYP2C19 genotypes, and clearance of amitriptyline through pathways other than biotransformation into nortriptyline was associated with CYP2D6 genotypes.	Nortriptyline	168-181	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	202-208
31688392-0	2019	Effects of Pharmacogenetic Screening for CYP2D6 Among Elderly Starting Therapy With Nortriptyline or Venlafaxine: A Pragmatic Randomized Controlled Trial (CYSCE Trial).	Nortriptyline	84-97	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	41-47
31688392-3	2019	The aim of this study was to determine the effectiveness of CYP2D6 pharmacogenetic screening to accelerate drug dosing in older patients with depression initiating nortriptyline or venlafaxine.	Nortriptyline	164-177	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	60-66
30452773-0	2019	Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline.	Nortriptyline	160-173	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	58-65
30452773-0	2019	Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline.	Nortriptyline	160-173	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	70-76
30452773-3	2019	The aim of this study was to evaluate the effects of CYP2C19 and CYP2D6 genetic polymorphisms on amitriptyline and nortriptyline pharmacokinetics.	Nortriptyline	115-128	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	53-60
30452773-3	2019	The aim of this study was to evaluate the effects of CYP2C19 and CYP2D6 genetic polymorphisms on amitriptyline and nortriptyline pharmacokinetics.	Nortriptyline	115-128	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	65-71
30452773-8	2019	The biotransformation of amitriptyline into nortriptyline was significantly different between subjects with the CYP2C19*2/*2, *2/*3, and *3/*3 genotypes and those with the other genotypes, with an estimated metabolic clearance of 17 and 61.5 L/h, respectively.	Nortriptyline	44-57	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	112-119
30452773-9	2019	Clearance of amitriptyline through pathways other than biotransformation into nortriptyline was estimated as 18.8 and 30.6 L/h for subjects with the CYP2D6*10/*10 and *10/*5 genotypes and those with the other genotypes, respectively.	Nortriptyline	78-91	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	149-155
30452773-10	2019	This study demonstrated a quantitative effect of the CYP2C19 and CYP2D6 genotypes on amitriptyline and nortriptyline pharmacokinetics.	Nortriptyline	103-116	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	53-60
30452773-10	2019	This study demonstrated a quantitative effect of the CYP2C19 and CYP2D6 genotypes on amitriptyline and nortriptyline pharmacokinetics.	Nortriptyline	103-116	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	65-71
30452773-11	2019	Production of nortriptyline from amitriptyline was associated with CYP2C19 genotypes, and clearance of amitriptyline through pathways other than biotransformation into nortriptyline was associated with CYP2D6 genotypes.	Nortriptyline	14-27	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	67-74
30145654-0	2018	NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine.	Nortriptyline	56-69	crystallin, gamma B	Mus musculus	0-3
30145654-9	2018	However, co-administration of NOP agonists blocked the antidepressant effects of SB-612111, fluoxetine, and nortriptyline, but not R-ketamine in the FST.	Nortriptyline	108-121	crystallin, gamma B	Mus musculus	30-33
30145654-12	2018	CONCLUSIONS: NOP receptor activation inhibits the acute antidepressant effects of nortriptyline and fluoxetine, but not R-ketamine.	Nortriptyline	82-95	crystallin, gamma B	Mus musculus	13-16
29895592-8	2018	This potency and selectivity profile is superior to Kir4.1 inhibitors amitriptyline, nortriptyline, and fluoxetine.	Nortriptyline	85-98	potassium inwardly-rectifying channel, subfamily J, member 10	Rattus norvegicus	52-58
30930625-9	2018	In addition to G2/M phase cell cycle arrest, NTP induced apoptosis as indicated by mitochondrial membrane potential and caspase-3 and annexin V assays.	Nortriptyline	45-48	caspase 3	Homo sapiens	120-129
30930625-9	2018	In addition to G2/M phase cell cycle arrest, NTP induced apoptosis as indicated by mitochondrial membrane potential and caspase-3 and annexin V assays.	Nortriptyline	45-48	annexin A5	Homo sapiens	134-143
30130674-2	2018	A previous study found that increased C-reactive protein (CRP), a marker of systemic inflammation, is associated with worse response to the serotonergic antidepressant escitalopram and better response to the noradrenergic antidepressant nortriptyline.	Nortriptyline	237-250	C-reactive protein	Homo sapiens	38-56
30130674-2	2018	A previous study found that increased C-reactive protein (CRP), a marker of systemic inflammation, is associated with worse response to the serotonergic antidepressant escitalopram and better response to the noradrenergic antidepressant nortriptyline.	Nortriptyline	237-250	C-reactive protein	Homo sapiens	58-61
30130674-6	2018	RESULTS: A higher polygenic risk score for CRP was associated with slightly better response to escitalopram and slightly worse response to nortriptyline, reflected in a statistically significant interaction between polygenic risk score and drug (beta = 1.07, 95% CI = 0.26-1.87, p = 0.0093).	Nortriptyline	139-152	C-reactive protein	Homo sapiens	43-46
28537967-8	2017	In CCI rats treated with both nortriptyline and morphine, the expression of alpha2A-adrenergic receptors, norepinephrine transporter, and tyrosine hydroxylase was markedly decreased in the locus coeruleus, whereas the norepinephrine concentration in the nucleus accumbens was remarkably increased.	Nortriptyline	30-43	tyrosine hydroxylase	Rattus norvegicus	76-158
28711409-0	2017	Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form.	Nortriptyline	0-13	synuclein alpha	Homo sapiens	56-71
30294185-4	2018	Although a voluminous literature of studies is available evaluating the role of benzodiazepines (clonazepam and antidepressant (nortriptyline) in the treatment of RLS, but to the best of our knowledge, no comparative study is available comparing both of these drugs for efficacy and safety for the treatment of RLS QoL among 40 + years old women.	Nortriptyline	128-141	RLS1	Homo sapiens	163-166
28296334-5	2017	The extent of hydroxylation of amitriptyline or nortriptyline was significantly reduced in subjects carrying two CYP2D6 decreased functional alleles compared with those with no or one decreased functional allele.	Nortriptyline	48-61	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	113-119
28520380-7	2012	Metabolism by CYP2C19 results in active metabolites, including nortriptyline, which is also a tricyclic antidepressant.	Nortriptyline	63-76	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	14-21
28616594-3	2017	In the present study, we used immunohistochemistry to examine alterations in c-Fos expression as a measure of neuronal activity in the mouse brain after acute administration of the antidepressant drugs nortriptyline or escitalopram (or saline as a control) with or without a subsequent TST session.	Nortriptyline	202-215	FBJ osteosarcoma oncogene	Mus musculus	77-82
28616594-4	2017	We found that without the TST session, nortriptyline administration enhanced the density of c-Fos-immunoreactive cells in regions of the central extended amygdala, paraventricular hypothalamic nucleus, and relevant regions of the brain stem, whereas escitalopram did not change c-Fos expression in any region.	Nortriptyline	39-52	FBJ osteosarcoma oncogene	Mus musculus	92-97
28616594-4	2017	We found that without the TST session, nortriptyline administration enhanced the density of c-Fos-immunoreactive cells in regions of the central extended amygdala, paraventricular hypothalamic nucleus, and relevant regions of the brain stem, whereas escitalopram did not change c-Fos expression in any region.	Nortriptyline	39-52	FBJ osteosarcoma oncogene	Mus musculus	278-283
27147301-7	2017	Pre- and post-reperfusion nortriptyline could reduce MDA and caspase-3 levels and normalise antioxidant enzymes activities, dose dependently.	Nortriptyline	26-39	caspase 3	Rattus norvegicus	61-70
26621261-6	2016	When analysing individual genes, we observed that changes in the expression of two genes (MMP28 and KXD1) were associated with better response to nortriptyline.	Nortriptyline	146-159	matrix metallopeptidase 28	Homo sapiens	90-95
27864362-6	2016	LPAR1 antagonists blocked GDNF mRNA expression and Galphai/o activation evoked by various classes of antidepressants (amitriptyline, nortriptyline, mianserin, and fluoxetine).	Nortriptyline	133-146	lysophosphatidic acid receptor 1	Rattus norvegicus	0-5
27864362-6	2016	LPAR1 antagonists blocked GDNF mRNA expression and Galphai/o activation evoked by various classes of antidepressants (amitriptyline, nortriptyline, mianserin, and fluoxetine).	Nortriptyline	133-146	glial cell derived neurotrophic factor	Rattus norvegicus	26-30
27207917-2	2016	METHODS: Here we measured absolute mRNA values (a reliable quantitation of number of molecules) of Macrophage Migration Inhibitory Factor and interleukin-1beta in a previously published sample from a randomized controlled trial comparing escitalopram vs nortriptyline (GENDEP) as well as in an independent, naturalistic replication sample.	Nortriptyline	254-267	macrophage migration inhibitory factor	Homo sapiens	99-137
27101231-0	2016	Relation between CYP2D6 Genotype, Phenotype and Therapeutic Drug Concentrations among Nortriptyline and Venlafaxine Users in Old Age Psychiatry.	Nortriptyline	86-99	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	17-23
27101231-1	2016	Objectives: To determine relations between drug concentrations and the cytochrome P450-CYP2D6 genotype or phenotype among elderly patients treated with nortriptyline or venlafaxine.	Nortriptyline	152-165	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	71-93
26632606-7	2016	In contrast, Kir4.1 inhibitor nortriptyline (100 muM), but not fluoxetine (100 muM), virtually abolished whole cell K(+)-selective conductance.	Nortriptyline	30-43	potassium inwardly-rectifying channel, subfamily J, member 10	Mus musculus	13-19
28033366-0	2016	A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline Pharmacotherapy.	Nortriptyline	118-131	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	68-74
28033366-1	2016	OBJECTIVE: Genotyping for CYP2D6 has the potential to predict differences in metabolism of nortriptyline.	Nortriptyline	91-104	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	26-32
27069625-7	2016	Furthermore, pretreatment of primary cortical neurons with amitriptyline and nortriptyline prevents the effects of the proinflammatory cytokine TNF-alpha (10 ng/mL) on neurite outgrowth and colocalization of synaptic proteins.	Nortriptyline	77-90	tumor necrosis factor	Rattus norvegicus	144-153
27069625-8	2016	These findings suggest that amitriptyline and nortriptyline can exert neurotrophic effects in primary cortical neurons via activation of a Trk/MAPK signaling pathway.	Nortriptyline	46-59	neurotrophic receptor tyrosine kinase 1	Rattus norvegicus	139-142
26621261-6	2016	When analysing individual genes, we observed that changes in the expression of two genes (MMP28 and KXD1) were associated with better response to nortriptyline.	Nortriptyline	146-159	KxDL motif containing 1	Homo sapiens	100-104
25636328-0	2015	Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial).	Nortriptyline	112-125	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	64-70
24287374-8	2014	Both antidepressants increased hippocampal 5-HT1B receptor binding; however, only nortriptyline selectively increased PFC 5-HT1A receptor binding.	Nortriptyline	82-95	5-hydroxytryptamine receptor 1A	Rattus norvegicus	122-128
26265436-6	2015	Current evidence suggests that genetic variability of the serotonergic biosynthesis enzyme tryptophan hydroxylase 2 (TPH2) and the serotonin transporter (SLC6A4) genes mediates the efficacy of several addiction treatments, such as ondansetron and disulfiram, and the antidepressants bupropion, nortriptyline and sertraline.	Nortriptyline	294-307	tryptophan hydroxylase 2	Homo sapiens	91-115
26265436-6	2015	Current evidence suggests that genetic variability of the serotonergic biosynthesis enzyme tryptophan hydroxylase 2 (TPH2) and the serotonin transporter (SLC6A4) genes mediates the efficacy of several addiction treatments, such as ondansetron and disulfiram, and the antidepressants bupropion, nortriptyline and sertraline.	Nortriptyline	294-307	tryptophan hydroxylase 2	Homo sapiens	117-121
26265436-6	2015	Current evidence suggests that genetic variability of the serotonergic biosynthesis enzyme tryptophan hydroxylase 2 (TPH2) and the serotonin transporter (SLC6A4) genes mediates the efficacy of several addiction treatments, such as ondansetron and disulfiram, and the antidepressants bupropion, nortriptyline and sertraline.	Nortriptyline	294-307	solute carrier family 6 member 4	Homo sapiens	131-152
26265436-6	2015	Current evidence suggests that genetic variability of the serotonergic biosynthesis enzyme tryptophan hydroxylase 2 (TPH2) and the serotonin transporter (SLC6A4) genes mediates the efficacy of several addiction treatments, such as ondansetron and disulfiram, and the antidepressants bupropion, nortriptyline and sertraline.	Nortriptyline	294-307	solute carrier family 6 member 4	Homo sapiens	154-160
25017001-2	2014	The authors tested the hypothesis that C-reactive protein (CRP), a commonly available marker of systemic inflammation, predicts differential response to escitalopram (a serotonin reuptake inhibitor) and nortriptyline (a norepinephrine reuptake inhibitor).	Nortriptyline	203-216	C-reactive protein	Homo sapiens	59-62
25017001-4	2014	CRP was measured with a high-sensitivity method in serum samples from 241 adult men and women with major depressive disorder randomly allocated to 12-week treatment with escitalopram (N=115) or nortriptyline (N=126).	Nortriptyline	194-207	C-reactive protein	Homo sapiens	0-3
24345533-0	2014	Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S,S)-[18F]FMeNER-D2.	Nortriptyline	40-53	solute carrier family 6 member 2	Homo sapiens	0-26
24345533-2	2014	Nortriptyline is a NET-selective tricyclic antidepressant (TCAs) that has been widely used for the treatment of depression.	Nortriptyline	0-13	solute carrier family 6 member 2	Homo sapiens	19-22
24345533-4	2014	In the present study, we used PET and (S,S)-[1818F]FMeNER-D2 to investigate NET occupancies in the thalamus in 10 patients with major depressive disorder taking various doses of nortriptyline, who were considered to be responders to the treatment.	Nortriptyline	178-191	solute carrier family 6 member 2	Homo sapiens	76-79
24345533-6	2014	The result showed approximately 50-70% NET occupancies in the brain as a result of the administration of 75-200 mg/d of nortriptyline.	Nortriptyline	120-133	solute carrier family 6 member 2	Homo sapiens	39-42
24345533-8	2014	Furthermore, as the minimum therapeutic level of plasma nortriptyline for the treatment of depression has been reported to be 70 ng/ml, our data indicate that this plasma nortriptyline concentration corresponds to approximately 50% NET occupancy measured with PET, suggesting that more than 50% of central NET occupancy would be appropriate for the nortriptyline treatment of patients with depression.	Nortriptyline	56-69	solute carrier family 6 member 2	Homo sapiens	232-235
24345533-8	2014	Furthermore, as the minimum therapeutic level of plasma nortriptyline for the treatment of depression has been reported to be 70 ng/ml, our data indicate that this plasma nortriptyline concentration corresponds to approximately 50% NET occupancy measured with PET, suggesting that more than 50% of central NET occupancy would be appropriate for the nortriptyline treatment of patients with depression.	Nortriptyline	56-69	solute carrier family 6 member 2	Homo sapiens	306-309
24345533-8	2014	Furthermore, as the minimum therapeutic level of plasma nortriptyline for the treatment of depression has been reported to be 70 ng/ml, our data indicate that this plasma nortriptyline concentration corresponds to approximately 50% NET occupancy measured with PET, suggesting that more than 50% of central NET occupancy would be appropriate for the nortriptyline treatment of patients with depression.	Nortriptyline	171-184	solute carrier family 6 member 2	Homo sapiens	232-235
24345533-8	2014	Furthermore, as the minimum therapeutic level of plasma nortriptyline for the treatment of depression has been reported to be 70 ng/ml, our data indicate that this plasma nortriptyline concentration corresponds to approximately 50% NET occupancy measured with PET, suggesting that more than 50% of central NET occupancy would be appropriate for the nortriptyline treatment of patients with depression.	Nortriptyline	171-184	solute carrier family 6 member 2	Homo sapiens	306-309
24345533-8	2014	Furthermore, as the minimum therapeutic level of plasma nortriptyline for the treatment of depression has been reported to be 70 ng/ml, our data indicate that this plasma nortriptyline concentration corresponds to approximately 50% NET occupancy measured with PET, suggesting that more than 50% of central NET occupancy would be appropriate for the nortriptyline treatment of patients with depression.	Nortriptyline	171-184	solute carrier family 6 member 2	Homo sapiens	232-235
24345533-8	2014	Furthermore, as the minimum therapeutic level of plasma nortriptyline for the treatment of depression has been reported to be 70 ng/ml, our data indicate that this plasma nortriptyline concentration corresponds to approximately 50% NET occupancy measured with PET, suggesting that more than 50% of central NET occupancy would be appropriate for the nortriptyline treatment of patients with depression.	Nortriptyline	171-184	solute carrier family 6 member 2	Homo sapiens	306-309
25017001-7	2014	For patients with low levels of CRP (<1 mg/L), improvement on the MADRS score was 3 points higher with escitalopram than with nortriptyline.	Nortriptyline	129-142	C-reactive protein	Homo sapiens	32-35
25017001-8	2014	For patients with higher CRP levels, improvement on the MADRS score was 3 points higher with nortriptyline than with escitalopram.	Nortriptyline	93-106	C-reactive protein	Homo sapiens	25-28
24779372-11	2014	Rs1045642, located on MDR1, is an ancestry-informative eQTL (P = 2.13E-13, using Fisher"s exact test) associated with adverse drug reactions to amitriptyline and nortriptyline and drug responses to morphine.	Nortriptyline	162-175	ATP binding cassette subfamily B member 1	Homo sapiens	22-26
24257813-6	2014	For those taking nortriptyline (n=161), the CYP2D6 genotype was significantly associated with nortriptyline and 10-hydroxynortriptyline serum concentrations and 10-hydroxynortriptyline:nortrip-tyline ratio.	Nortriptyline	17-30	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	44-50
24257813-6	2014	For those taking nortriptyline (n=161), the CYP2D6 genotype was significantly associated with nortriptyline and 10-hydroxynortriptyline serum concentrations and 10-hydroxynortriptyline:nortrip-tyline ratio.	Nortriptyline	94-107	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	44-50
24257813-6	2014	For those taking nortriptyline (n=161), the CYP2D6 genotype was significantly associated with nortriptyline and 10-hydroxynortriptyline serum concentrations and 10-hydroxynortriptyline:nortrip-tyline ratio.	Nortriptyline	185-199	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	44-50
24972362-10	2014	With nortriptyline, 1/10 (10%) remitted with nortriptyline+lithium, and 1/5 (20%) when phenelzine was added.	Nortriptyline	5-18	WD repeat and HMG-box DNA binding protein 1	Homo sapiens	68-75
23611809-6	2013	UGT2B10 was inactive in the glucuronidation of desipramine, nortriptyline, carbamazepine, and afloqualone.	Nortriptyline	60-73	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	0-7
24037379-3	2013	Here we present the crystal structure of the Drosophila melanogaster dopamine transporter at 3.0 A resolution bound to the tricyclic antidepressant nortriptyline.	Nortriptyline	148-161	Dopamine transporter	Drosophila melanogaster	69-89
23799451-0	2013	Novel CYP2D6 and CYP2C19 variants identified in a patient with adverse reactions towards venlafaxine monotherapy and dual therapy with nortriptyline and fluoxetine.	Nortriptyline	135-148	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	6-12
23799451-0	2013	Novel CYP2D6 and CYP2C19 variants identified in a patient with adverse reactions towards venlafaxine monotherapy and dual therapy with nortriptyline and fluoxetine.	Nortriptyline	135-148	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	17-24
23978467-10	2013	This indirect anti-TNFalpha action was observed with the tricyclic antidepressant nortriptyline, the selective serotonin and noradrenaline reuptake inhibitor venlafaxine and the beta2-AR agonist terbutaline.	Nortriptyline	82-95	tumor necrosis factor	Mus musculus	19-27
23708883-11	2013	Of the ARS 2-point anticholinergics, nortriptyline was prescribed most frequently.	Nortriptyline	37-50	serrate, RNA effector molecule	Homo sapiens	7-12
23425522-3	2013	Nortriptyline, which blocks the SCN5A-encoded cardiac sodium channel, may exemplify such drugs.	Nortriptyline	0-13	sodium voltage-gated channel alpha subunit 5	Homo sapiens	32-37
23486447-3	2013	These drugs and their metabolites, along with desipramine and nortriptyline, undergo hydroxylation by CYP2D6 to less active metabolites.	Nortriptyline	62-75	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	102-108
22750346-1	2012	To know the interaction of amphiphilic drugs nortriptyline hydrochloride (NOT) and promazine hydrochloride (PMZ) with serum albumins (i.e., human serum albumin (HSA) and bovine serum albumin (BSA)), techniques of UV-visible, fluorescence, and circular dichroism (CD) spectroscopies are used.	Nortriptyline	45-72	albumin	Homo sapiens	118-131
22750346-1	2012	To know the interaction of amphiphilic drugs nortriptyline hydrochloride (NOT) and promazine hydrochloride (PMZ) with serum albumins (i.e., human serum albumin (HSA) and bovine serum albumin (BSA)), techniques of UV-visible, fluorescence, and circular dichroism (CD) spectroscopies are used.	Nortriptyline	45-72	albumin	Homo sapiens	146-159
21999196-1	2012	WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: A single nucleotide polymorphism in ABCB1, which encodes P-glycoprotein, has retrospectively been associated with symptoms of nortriptyline-induced postural hypotension in depressed patients.	Nortriptyline	168-181	ATP binding cassette subfamily B member 1	Homo sapiens	78-83
21999196-1	2012	WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: A single nucleotide polymorphism in ABCB1, which encodes P-glycoprotein, has retrospectively been associated with symptoms of nortriptyline-induced postural hypotension in depressed patients.	Nortriptyline	168-181	ATP binding cassette subfamily B member 1	Homo sapiens	99-113
21999196-14	2012	At t(max) at 8 h post dose, nortriptyline increased the heart rate response to posture change in all subjects with mean (95% CI) Delta heart rate values of 7.4 (3.6, 11.3) beats min(-1) on active standing (P = 0.0009) and 4.8 (2.0, 7.6) beats min(-1) on head-up tilt (P = 0.002), but no difference was observed between haplotype groups.	Nortriptyline	28-41	CD59 molecule (CD59 blood group)	Homo sapiens	178-184
21999196-14	2012	At t(max) at 8 h post dose, nortriptyline increased the heart rate response to posture change in all subjects with mean (95% CI) Delta heart rate values of 7.4 (3.6, 11.3) beats min(-1) on active standing (P = 0.0009) and 4.8 (2.0, 7.6) beats min(-1) on head-up tilt (P = 0.002), but no difference was observed between haplotype groups.	Nortriptyline	28-41	CD59 molecule (CD59 blood group)	Homo sapiens	243-249
21999196-16	2012	CONCLUSION: The association between ABCB1 polymorphisms and nortriptyline-induced postural hypotension found in the previous study could not be confirmed.	Nortriptyline	60-73	ATP binding cassette subfamily B member 1	Homo sapiens	36-41
21999196-3	2012	WHAT THIS STUDY ADDS: In a prospective study of healthy volunteers homozygous for ABCB1 (1236-2677-3435, TTT/TTT or CGC/CGC), a single dose of nortriptyline was administered, plasma exposure was determined and blood pressure and heart rate were monitored during posture change.	Nortriptyline	143-156	ATP binding cassette subfamily B member 1	Homo sapiens	82-87
21999196-7	2012	The association between ABCB1 polymorphisms and nortriptyline-induced postural hypotension found in a previous study could not be confirmed.	Nortriptyline	48-61	ATP binding cassette subfamily B member 1	Homo sapiens	24-29
21999196-9	2012	AIMS To investigate the influence of ABCB1 (1236-2677-3435) polymorphisms on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers.	Nortriptyline	77-90	ATP binding cassette subfamily B member 1	Homo sapiens	37-42
21999196-10	2012	METHODS: Genetic screening of 67 healthy volunteers identified eight CGC homozygotes and nine TTT homozygotes of ABCB1 (1236-2677-3435), who were administered a single dose of nortriptyline 25 mg.	Nortriptyline	176-189	ATP binding cassette subfamily B member 1	Homo sapiens	113-118
21262863-8	2011	Nortriptyline dose-dependently blocked hERG current, with a tail IC(50) value of 2.20 +- 0.09 muM (n = 4).	Nortriptyline	0-13	ETS transcription factor ERG	Homo sapiens	39-43
21658141-0	2012	Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation.	Nortriptyline	86-99	solute carrier family 6 member 4	Homo sapiens	24-45
21658141-1	2012	AIMS: We investigated whether variants in the serotonin transporter gene (SLC6A4) influence smoking cessation rates using antidepressant therapy (i.e. bupropion and nortriptyline).	Nortriptyline	165-178	solute carrier family 6 member 4	Homo sapiens	46-67
21658141-11	2012	CONCLUSIONS: Bupropion and nortriptyline seem to be more effective in smoking cessation among SLC6A4 high-activity variant carriers, probably by blocking the increased serotonin transporter activity, thereby increasing serotonin levels.	Nortriptyline	27-40	solute carrier family 6 member 4	Homo sapiens	94-100
21658141-11	2012	CONCLUSIONS: Bupropion and nortriptyline seem to be more effective in smoking cessation among SLC6A4 high-activity variant carriers, probably by blocking the increased serotonin transporter activity, thereby increasing serotonin levels.	Nortriptyline	27-40	solute carrier family 6 member 4	Homo sapiens	168-189
21854846-0	2011	Risk assessment of accidental nortriptyline poisoning: the importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator.	Nortriptyline	93-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	73-88
21854846-1	2011	It is not possible to make a prospective clinical study that reveals the importance of the nortriptyline metabolising cytochrome P450 (CYP) isoforms (CYP1A2, CYP2C19, CYP2D6, and CYP3A4) in relation to attaining potential toxic nortriptyline concentrations with a possibly fatal outcome.	Nortriptyline	91-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-133
21854846-1	2011	It is not possible to make a prospective clinical study that reveals the importance of the nortriptyline metabolising cytochrome P450 (CYP) isoforms (CYP1A2, CYP2C19, CYP2D6, and CYP3A4) in relation to attaining potential toxic nortriptyline concentrations with a possibly fatal outcome.	Nortriptyline	91-104	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-138
21854846-1	2011	It is not possible to make a prospective clinical study that reveals the importance of the nortriptyline metabolising cytochrome P450 (CYP) isoforms (CYP1A2, CYP2C19, CYP2D6, and CYP3A4) in relation to attaining potential toxic nortriptyline concentrations with a possibly fatal outcome.	Nortriptyline	228-241	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-138
21854846-7	2011	Of the investigated factors, the simulations indicate that having CYP2D6 PM status is a major risk factor for attaining high concentrations and thereby possibly becoming poisoned by nortriptyline.	Nortriptyline	182-195	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	66-72
21854846-10	2011	The results point towards the combination of low CYP3A4 activity and CYP2D6 PM status of major importance for attaining possibly toxic nortriptyline concentrations.	Nortriptyline	135-148	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-55
21854846-10	2011	The results point towards the combination of low CYP3A4 activity and CYP2D6 PM status of major importance for attaining possibly toxic nortriptyline concentrations.	Nortriptyline	135-148	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	69-75
21854846-12	2011	In a clinical context, the simulations suggest that precise individual dose adjustment of nortriptyline requires information regarding the activity of both CYP3A4 and CYP2D6.	Nortriptyline	90-103	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	156-162
21854846-12	2011	In a clinical context, the simulations suggest that precise individual dose adjustment of nortriptyline requires information regarding the activity of both CYP3A4 and CYP2D6.	Nortriptyline	90-103	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	167-173
21300705-0	2011	Nortriptyline reverses corticosteroid insensitivity by inhibition of phosphoinositide-3-kinase-delta.	Nortriptyline	0-13	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	69-100
21262856-3	2011	Here, we further test the hypothesis of BDNF involvement in antidepressant action in a genetic rat model of depression after chronic oral treatment with escitalopram, nortriptyline or placebo.	Nortriptyline	167-180	brain-derived neurotrophic factor	Rattus norvegicus	40-44
21614669-1	2011	INTRODUCTION: Amitriptyline and its metabolite, nortriptyline, are metabolized, in part, by CYP2D6, a polymorphic enzyme.	Nortriptyline	48-61	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	92-98
21614669-6	2011	Patients taking tricyclic antidepressants who are homozygous for CYP2D6*4 demonstrate >3 times concentration-time curve (AUCs) and prolonged elimination half-lives, especially of secondary amines such as nortriptyline.	Nortriptyline	207-220	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	65-71
21300705-9	2011	In addition, nortriptyline inhibited PI3Kdelta activity, but had no effect on the PI3Kalpha and PI3Kgamma isoforms.	Nortriptyline	13-26	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	37-46
21300705-11	2011	Nortriptyline restores corticosteroid sensitivity induced by oxidative stress via direct inhibition of PI3Kdelta and is a potential treatment for corticosteroid-insensitive diseases such as COPD and severe asthma.	Nortriptyline	0-13	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	103-112
21346604-0	2011	CYP 2D6 PM status and antidepressant response to nortriptyline and venlafaxine: is it more than just drug metabolism?	Nortriptyline	49-62	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-7
20808132-2	2011	A randomized controlled trial of nortriptyline, paroxetine, and placebo for the treatment of depression in PD (dPD) was recently completed.	Nortriptyline	33-46	dachs	Drosophila melanogaster	111-114
20970119-8	2011	Several polymorphisms in the protein phosphatase 1A gene (PPM1A) remained significantly associated with response to nortriptyline in humans after correction for multiple comparisons within the gene.	Nortriptyline	116-129	protein phosphatase, Mg2+/Mn2+ dependent 1A	Homo sapiens	29-51
20970119-8	2011	Several polymorphisms in the protein phosphatase 1A gene (PPM1A) remained significantly associated with response to nortriptyline in humans after correction for multiple comparisons within the gene.	Nortriptyline	116-129	protein phosphatase, Mg2+/Mn2+ dependent 1A	Homo sapiens	58-63
20056557-11	2010	After about 10 days of treatment, nortriptyline suppressed this allodynia in both wild-type and MOR-deficient mice.	Nortriptyline	34-47	opioid receptor, mu 1	Mus musculus	96-99
21696712-0	2011	Combination treatment of mice with CRx-153 (nortriptyline and desloratadine) decreases the severity of experimental autoimmune encephalomyelitis.	Nortriptyline	44-57	cone-rod homeobox	Mus musculus	35-38
21696712-4	2011	The findings show that combination treatment with desloratadine and nortriptyline decreases the mean clinical score, disease relapse frequency, and number of CD4(+) T cells infiltrating into the CNS.	Nortriptyline	68-81	CD4 antigen	Mus musculus	158-161
21696712-7	2011	The data also show that combination treatment with desloratadine and nortriptyline inhibits the production of IFN-gamma and IL-17 produced by naive CD4(+) T cells activated in the presence of Th1 cell- and Th17 cell-promoting conditions, while increasing the level of IL-4 produced by naive CD4(+) T cells activated in the presence of Th2 cell-promoting conditions.	Nortriptyline	69-82	interferon gamma	Mus musculus	110-119
21696712-7	2011	The data also show that combination treatment with desloratadine and nortriptyline inhibits the production of IFN-gamma and IL-17 produced by naive CD4(+) T cells activated in the presence of Th1 cell- and Th17 cell-promoting conditions, while increasing the level of IL-4 produced by naive CD4(+) T cells activated in the presence of Th2 cell-promoting conditions.	Nortriptyline	69-82	interleukin 17A	Mus musculus	124-129
21696712-7	2011	The data also show that combination treatment with desloratadine and nortriptyline inhibits the production of IFN-gamma and IL-17 produced by naive CD4(+) T cells activated in the presence of Th1 cell- and Th17 cell-promoting conditions, while increasing the level of IL-4 produced by naive CD4(+) T cells activated in the presence of Th2 cell-promoting conditions.	Nortriptyline	69-82	CD4 antigen	Mus musculus	148-151
21696712-7	2011	The data also show that combination treatment with desloratadine and nortriptyline inhibits the production of IFN-gamma and IL-17 produced by naive CD4(+) T cells activated in the presence of Th1 cell- and Th17 cell-promoting conditions, while increasing the level of IL-4 produced by naive CD4(+) T cells activated in the presence of Th2 cell-promoting conditions.	Nortriptyline	69-82	interleukin 4	Mus musculus	268-272
21696712-7	2011	The data also show that combination treatment with desloratadine and nortriptyline inhibits the production of IFN-gamma and IL-17 produced by naive CD4(+) T cells activated in the presence of Th1 cell- and Th17 cell-promoting conditions, while increasing the level of IL-4 produced by naive CD4(+) T cells activated in the presence of Th2 cell-promoting conditions.	Nortriptyline	69-82	CD4 antigen	Mus musculus	291-294
21098865-0	2010	Cytosolic phospholipase A2 inhibition is involved in the protective effect of nortriptyline in primary astrocyte cultures exposed to combined oxygen-glucose deprivation.	Nortriptyline	78-91	phospholipase A2 group IVA	Rattus norvegicus	0-26
21098865-3	2010	The aim of the present study was to determine whether treatment with low or medium concentrations of nortriptyline (0.1-10 muM) might have an effect on cPLA2 protein and/or mRNA expression in ischemic astrocytes, and whether this influence might be related to its potential positive influence on cell viability.	Nortriptyline	101-114	phospholipase A2 group IVA	Rattus norvegicus	152-157
21098865-6	2010	We have demonstrated that nortriptyline influences a decrease in cPLA2-mediated arachidonic acid (AA) release through a mechanism that appears to involve the attenuation of both PKC and Erk1/2 kinase expression.	Nortriptyline	26-39	phospholipase A2 group IVA	Rattus norvegicus	65-70
21098865-6	2010	We have demonstrated that nortriptyline influences a decrease in cPLA2-mediated arachidonic acid (AA) release through a mechanism that appears to involve the attenuation of both PKC and Erk1/2 kinase expression.	Nortriptyline	26-39	protein kinase C, gamma	Rattus norvegicus	178-181
21098865-6	2010	We have demonstrated that nortriptyline influences a decrease in cPLA2-mediated arachidonic acid (AA) release through a mechanism that appears to involve the attenuation of both PKC and Erk1/2 kinase expression.	Nortriptyline	26-39	mitogen activated protein kinase 3	Rattus norvegicus	186-192
21098865-9	2010	Our findings document a role for cPLA2 expression attenuation and AA release inhibition in the protective effect of nortriptyline in ischemic astrocytes.	Nortriptyline	116-129	phospholipase A2 group IVA	Rattus norvegicus	33-38
20056557-13	2010	An acute injection of the DOR antagonist naltrindole induced a relapse of neuropathic allodynia in both wild-type and MOR-deficient mice, thus confirming the critical role of DORs in nortriptyline action.	Nortriptyline	183-196	opioid receptor, delta 1	Mus musculus	26-29
20363235-4	2010	Amitriptyline, nortriptyline and imipramine showed considerably higher affinities for alpha(1A)- (approximately 25- to 80-fold) and alpha(1D)-adrenoceptors (approximately 10- to 25-fold) than for alpha(1B)-adrenoceptors in both contraction and [(3)H]prazosin binding assays with rat native and human receptors, respectively.	Nortriptyline	15-28	calcium voltage-gated channel subunit alpha1 A	Homo sapiens	86-94
20363235-5	2010	In addition, amitriptyline, nortriptyline and imipramine were substantially more potent in the inhibition of noradrenaline-induced intracellular Ca(2+) increases in HEK-293 cells expressing alpha(1A)- or a truncated version of alpha(1D)-adrenoceptors which traffics more efficiently towards the cell membrane than in cells expressing alpha(1B)-adrenoceptors.	Nortriptyline	28-41	calcium voltage-gated channel subunit alpha1 A	Homo sapiens	190-198
21793326-4	2010	Nortriptyline-induced Ca2+ influx was inhibited by the store-operated Ca2+ channel blockers econazole and SK&F96365, the phospholipase A2 inhibitor aristolochic acid, and alteration of activity of protein kinase C. In Ca2+-free medium, 200 microM nortriptyline pretreatment greatly inhibited the rise of [Ca2+]i induced by the endoplasmic reticulum Ca2+ pump inhibitor thapsigargin.	Nortriptyline	0-13	phospholipase A2	Oryctolagus cuniculus	125-141
20309528-3	2010	OBJECTIVE: In this study, the occupancy of NET by different doses of an antidepressant, nortriptyline, was measured using positron emission tomography (PET) with (S,S)-[(18)F]FMeNER-D(2).	Nortriptyline	88-101	solute carrier family 6 member 2	Homo sapiens	43-46
20309528-10	2010	RESULTS: Mean NET occupancies by nortriptyline were 16.4% at 10 mg, 33.2% at 25 mg, and 41.1% at 75 mg.	Nortriptyline	33-46	solute carrier family 6 member 2	Homo sapiens	14-17
20309528-13	2010	CONCLUSIONS: NET occupancy by nortriptyline corresponding to the administration dose of 10-75 mg or plasma concentration was observed from 16% to 41%.	Nortriptyline	30-43	solute carrier family 6 member 2	Homo sapiens	13-16